Quantcast

Latest gastrointestinal stromal tumor Stories

2008-12-19 18:41:00

Use of Gleevec after surgery shows significant benefit for gastrointestinal stromal tumor (GIST) patients, dramatically reducing risk of relapse GIST, a life-threatening cancer, recurs in as many as one of two patients; recurrent tumors are often more aggressive than primary tumors For GIST patients who were assigned to Gleevec, more than nine out of 10 remained cancer-free based on a 14-month median follow up EAST HANOVER, N.J., Dec. 19 /PRNewswire/ -- Novartis announced today...

2008-10-27 12:00:30

Infinity Pharmaceuticals, a cancer drug discovery and development company, has initiated a Phase III registration trial of IPI-504, its lead inhibitor of heat shock protein 90, in patients with refractory gastrointestinal stromal tumors. The Ring trial is a randomized, double-blind, placebo-controlled study evaluating approximately 200 patients with refractory gastrointestinal stromal tumors (GIST) in over 20 countries and 50 sites worldwide. Patients whose tumors have grown despite...

2008-09-08 18:00:09

Pfizer announced today that important study results involving the company's leading anticancer agent, SUTENT(R) (sunitinib malate), as well as data examining an investigational agent, CP-751,871, will be presented at the 33rd European Society for Medical Oncology (ESMO) Congress in Stockholm, 12--16 September 2008. Researchers will present results of several analyses evaluating the cost effectiveness of SUTENT(R) as first-line therapy in patients with metastatic renal cell carcinoma...

2008-08-27 09:00:23

EAST HANOVER, N.J., Aug. 27 /PRNewswire/ -- Novartis announced today that Gleevec(R) (imatinib mesylate) tablets* has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST). FDA priority review status is granted to therapies that could potentially fill a currently unmet medical need and accelerates the standard review timing from ten to six months(1)....

2008-07-02 09:00:13

Rationale: Platelet-derived growth factor (PDGF) promotes the proliferation and migration of pulmonary artery smooth muscle cells (PASMCs), and may play a role in the progression of pulmonary arterial hypertension (PAH), a condition characterized by proliferation of PASMCs resulting in the obstruction of small pulmonary arteries. Objectives: To analyze the expression and pathogenic role of PDGF in idiopathic PAH. Methods: PDGF and PDGF receptor mRNA expression was studied by real-time...

2008-06-05 03:00:07

By Edwards, Michael A Beatty, John S; Shah, Malay B; Bittner, James G IV To the Editor: Non-epithelial mesenchymal tumors, including gastrointestinal stromal tumors (GISTs) and smooth muscle tumors (SMTs), are rare and may occur in any part of the alimentary tract.1 GISTs originate from the interstitial cell of Cajal, an intestinal pacemaker cell, and represent 1 per cent to 3 per cent of all gastrointestinal malignant tumors. Approximately 5 per cent of GISTs occur in the colon and rectum...

2007-08-16 06:16:45

By Liu, Lina Qian, Junqi; Singh, Harpreet; Meiers, Isabelle; Et al Context.-The separation of chromophobe renal cell carcinoma, oncocytoma, and clear cell renal cell carcinoma using light microscopy remains problematic in some cases. Objective.-To determine a practical immunohistochemical panel for the differential diagnosis of chromophobe carcinoma. Design.-Vimentin, glutathione S-transferase alpha (GST-alpha), CD10, CD117, cytokeratin (CK) 7, and epithelial cell adhesion molecule...

2006-07-23 14:45:00

By Maggie Fox, Health and Science Correspondent WASHINGTON (Reuters) - Gleevec, the pill that transformed cancer treatments by offering an easy way to target a difficult type of leukemia, may cause serious heart damage, researchers cautioned on Sunday. They found evidence that treatment caused heart failure in 10 patients who took Gleevec, made by Swiss drugmaker Novartis. Patients should not stop taking the drug, known generically as imatinib, but should be watched closely for heart damage,...

89d7ddf2b7a291cf1da22844fcc1d77b1
2006-07-23 12:05:00

By Maggie Fox, Health and Science Correspondent WASHINGTON -- Gleevec, the pill that transformed cancer treatments by offering an easy way to target a difficult type of leukemia, may cause serious heart damage, researchers cautioned on Sunday. They found evidence that treatment caused heart failure in 10 patients who took Gleevec, made by Swiss drugmaker Novartis. Patients should not stop taking the drug, known generically as imatinib, but should be watched closely for heart damage, the team...

2006-05-11 11:27:25

LONDON/ZURICH (Reuters) - Glivec (imatinib), which has dramatically improved survival prospects for some cancer patients, can interfere with bone development, according to U.S. researchers. Results of a study published this week in The New England Journal of Medicine indicated that the drug inhibits bone formation and resorption -- a process known as bone remodelling. Novartis has not found similar adverse effects in a large database it keeps of clinical trials and post-marketing...


Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'